March 19, 2013
DEPARTMENT CIRCULAR
No. 2013 – 0132
NATIONAL
COUNCIL FOR BLOOD SERVICES – TECHNICAL COMMITTEE
RECOMMENDATIONS, STRATEGIES,
METHODOLOGIES AND ALGORITHMS FOR TESTING BLOOD
UNITS FOR TRANSFUSION TRANSMISSIBLE INFECTION
In order to establish a
reliable, effective and appropriate testing of blood units and to implement
quality–assured testing for Transfusion Transmissible Infection (TTI), the
National Council for Blood Services – Technical Committee chaired by Dr.
Elizabeth Y. Arcellana – Nuqui recommends the following testing strategies,
methodologies and testing algorithms, mainly aligned with WHO Recommendations
on Screening Donated Blood for Transfusion Transmissible Infections, to be
adopted by all Blood Service Facilities.
Please be guided
accordingly.
Strategies and
Recommendations:
1. All whole blood
and apheresis donations shall be tested for evidence of TTI prior to release
for cross–matching and transfusion.
2. Testing of all
blood donations shall be mandatory for the following infections and shall be
run simultaneously or in parallel using the following serological markers:
· HIV–1 and HIV–2:
either a combination of HIV antigen–antibody or HIV antibodies
· Hepatitis B:
Hepatitis B surface antigen (HBsAg)
· Hepatitis C: either
a combination of HCV antigen–antibody or HCV antibodies
· Syphilis
(Treponema pallidum): screening for specific treponemal antibodies.
· Malaria:
screening for antigen or antibody or demonstration of the parasite in a thick
and thin blood smear
3. All testing of
blood donations for TTIs shall be carried out only on samples taken from the
blood unit and in quality controlled environment.
4. If found
initially reactive to any of the TTIs and the test is valid, the blood unit
shall be referred to National Voluntary Blood Services Program – National
Reference Laboratory (NVBSP – NRL) for confirmatory testing. If the testing is
performed following strict guidelines and under quality–assured conditions,
there is no need to repeat test in duplicate. Please refer to the new testing
algorithm.
5. Only licensed
BSFs shall be allowed to test blood for the five (5) mandatory TTIs. Where
feasible, blood testing shall be centralized in identified Lead Blood Service
Facilities to achieve uniformity of standards, increased safety and economies
of scale.
6. The minimum
evaluated sensitivity and specificity levels of all assays used for blood
screening shall be as high as possible and preferably not less than 99.5% with
Certificate of Product Registration from Food and Drug Administration (FDA) and
proof of Kit Evaluation from STD AIDS Cooperative Central Laboratory (SACCL).
Only reagent kits with current and valid certificates of product registration
and SACCL evaluation shall be used in screening blood units for TTIs.
7. Quality–assured
testing of all donations using serology shall be in place before testing
strategies utilizing nucleic acid testing are considered.
8. Only blood and
blood components that are nonreactive in all five (5) mandatory TTIs shall be
released for cross–matching and transfusion.
9. All blood unit
tested reactive for TTI shall be properly labelled and stored separately until
discarded safely and appropriately or sent to NVBSP – NRL for confirmatory
testing. Furthermore, blood units tested reactive for HBsAg under the test kits
and criteria listed under Department Circular 2012 – 0198 shall no longer be
sent to NVBSP – NRL for further testing.
10. Blood units tested to syphilis shall not be refereed
nor sent to NVBSP – NRL for further testing.
11. Blood unit tested reactive by methods that do not
conform to the guidelines herein shall not be accepted for further testing by
the NVBSP – NRL.
12. Blood unit shall not be retested by transfusing
facility or by other BSF provided the source BSF tested the blood units in
conformity with the guidelines herein, and that the retesting BSF should also
meet the guidelines herein.
13. All staff performing TTI testing shall have undergone
training and passed proficiency testing offered by the NVBSP – NRL or SACCL.
Only trained and proficient staff shall perform testing of donated blood units
for TTIs.
Blood
Service Facilities which are found to be using unlicensed or unregistered
testing kits shall have their license to operate suspended or revoked by the
Bureau of Health Facility Services (BHFS).
Methodology:
1. Human
Immunodeficiency Virus:
· Testing shall be
performed using a highly sensitive and specific anti–HIV–1 + anti –HIV–2
immunoassay or HIV combination antigen–antibody immunoassay (EIA/CLIA). The assay shall be capable of detecting
subtypes specific to the country or region.
TTI
|
Testing Marker
|
Recommended
Assay
|
Comments
|
HIV
|
Anti – HIV (1,2,O) or
combination of Anti – HIV (1,2,O) and HIV p24 antigen
|
Immunoassay
|
Testing for HIV antibody
is recommended as minimum standard for blood safety but at present, the most
sensitive HIV serological assay is a combined detection of antigen (p24
antigen) and antibody (anti–HIV–1 and
–2). These assays are considered to be the most effective for the
serological testing of donated blood.
|
2. Hepatitis
B
· Testing shall be
performed using a highly sensitive and specific HBsAg immunoassay (EIA/CLIA).
· Testing for anti–HBc
and ALT is not recommended
TTI
|
Testing Marker
|
Recommended
Assay
|
Comments
|
Hepatitis
B
|
HBsAg
|
Immunoassay
|
HBsAg is the first
serological marker of HBV and its determination is recommended as minimum
standard for blood safety.
|
3. Hepatitis
C
· Testing shall be
performed using a highly sensitive and specific HCV antibody immunoassay or a
combination HCV antigen–antibody immunoassay (EIA/CLIA). The assay shall be
capable of detecting genotypes specific to the country of origin.
TTI
|
Testing Marker
|
Recommended
Assay
|
Comments
|
Hepatitis
C
|
Anti – HCV
or
Combination of Anti –
HCV and HCV antigen
|
Immunoassay
|
The most sensitive and
effective for the HCV serological testing of blood donation is a combined
detection of antigen and antibody however due to limited number of
commercially available assays, testing for HCV antibody is recommended as
minimum standard for blood safety.
|
4. Syphilis
· Testing shall be
performed using a highly sensitive and specific test for treponemal antibodies:
either TPHA or enzyme immunoassay
TTI
|
Testing Marker
|
Recommended
Assay
|
Comments
|
Syphilis
|
Antibody to
Treponema
pallidum
|
Particle
Agglutination
Immunoassay
|
Testing for specific
treponemal antibody is recommended as minimum standard for blood safety.
|
5. Malaria
· All donations
shall be tested for evidence of malarial antigen using a
highly sensitive enzyme immunoassay or for parasitemia using thick blood films.
TTI
|
Testing Marker
|
Recommended
Assay
|
Comments
|
Malaria
|
Malarial antigen or
antibody
Presence of
malarial
parasite
|
Immunoassay
EIA
Nonmicroscopic
Rapid Test
Smear
Microscopy
|
High quality, sensitive
malaria antigen assay may be better able to identify parasitemic donations,
including those with much lower levels of parasites than are reliably
detectable by thick film, however, direct detection of parasite by thick and
thin smear is still recommended as minimum standard for blood safety.
|
No comments:
Post a Comment